Docoh
Loading...

TLGT Teligent

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.

Company profile

Ticker
TLGT
Exchange
CEO
Timothy Sawyer
Employees
Incorporated
Location
Fiscal year end
Former names
IGI INC, IGI LABORATORIES, INC
SEC CIK
IRS number
10355758

TLGT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

24 May 21
4 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Teligent earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 28.31M 28.31M 28.31M 28.31M 28.31M 28.31M
Cash burn (monthly) (positive/no burn) (positive/no burn) 2.99M 10.9M 3.62M 2.06M
Cash used (since last report) n/a n/a 12.37M 45.1M 14.99M 8.51M
Cash remaining n/a n/a 15.94M -16.79M 13.32M 19.8M
Runway (months of cash) n/a n/a 5.3 -1.5 3.7 9.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Jul 21 Pate R Carter RSU Common Stock Grant Aquire A No No 0 150,000 0 150,000
21 Jul 21 Marth William S RSU Common Stock Grant Aquire A No No 0 150,000 0 150,000
21 Jul 21 Thomas J Sabatino JR RSU Common Stock Grant Aquire A No No 0 150,000 0 150,000
21 Jul 21 Ben-maimon Carole RSU Common Stock Grant Aquire A No No 0 150,000 0 150,000
21 Jul 21 John E Celentano RSU Common Stock Grant Aquire A No No 0 150,000 0 150,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 25 3 +733.3%
Opened positions 24 2 +1100.0%
Closed positions 2 20 -90.0%
Increased positions 1 0 NEW
Reduced positions 0 1 EXIT
13F shares
Current Prev Q Change
Total value 7.77M 1.53M +408.8%
Total shares 12.34M 2.04M +506.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Nantahala Capital Management 4.16M $2.58M NEW
Silverback Asset Management 3.85M $2.4M NEW
Eversept Partners 2.5M $1.56M NEW
Renaissance Technologies 450.94K $281K NEW
Vanguard 389.08K $242K NEW
VIRT Virtu Financial 248.71K $155K NEW
Geode Capital Management 242.06K $150K NEW
NTRS Northern Trust 126.5K $79K NEW
BK Bank Of New York Mellon 92.41K $57K NEW
BLK Blackrock 79.56K $50K NEW
Largest transactions
Shares Bought/sold Change
Nantahala Capital Management 4.16M +4.16M NEW
Silverback Asset Management 3.85M +3.85M NEW
Eversept Partners 2.5M +2.5M NEW
Ubs Oconnor 0 -2M EXIT
Renaissance Technologies 450.94K +450.94K NEW
Vanguard 389.08K +389.08K NEW
VIRT Virtu Financial 248.71K +248.71K NEW
Geode Capital Management 242.06K +242.06K NEW
NTRS Northern Trust 126.5K +126.5K NEW
BK Bank Of New York Mellon 92.41K +92.41K NEW

Financial report summary

?
Risks
  • There is substantial doubt about our ability to continue as a going concern.
  • In the event we were to pursue an in-court bankruptcy reorganization under the U.S. Bankruptcy Code, we would be subject to the risks and uncertainties associated with bankruptcy proceedings, including the potential delisting of our common stock from trading on Nasdaq.
  • Our stock price is, and we expect it to remain, volatile and subject to wide fluctuations, which may make it difficult for stockholders to sell shares of common stock at or above the price for which they were acquired.
  • The Series D Preferred Stock ranks senior to our common stock with respect to dividends, distributions and liquidation. In addition, the conversion of our shares of Series D Preferred Stock could cause substantial dilution to the holders of shares of our common stock.
  • We may need to raise additional funds in the future, which may not be available on acceptable terms or at all.
  • Shares of our common stock can be relatively illiquid which may affect the trading price of our common stock.
  • Our principal stockholders own a significant percentage of our stock and will be able to exercise significant influence over our affairs.
  • Due to the concentration of common stock owned by significant stockholders, the sale of such stock might adversely affect the price of our common stock.
  • We have not paid dividends to our common stockholders in the past nor do we expect to pay dividends in the foreseeable future, and any return on investment may be limited to potential future appreciation on the value of our common stock.
Management Discussion
  • We had net income of $2.2 million, or $0.04 per share, for the three months ended March 31, 2021 (the "Current Period"), compared to a net loss of $26.8 million, or $4.98 per share, for the three months ended March 31, 2020 (the "Prior Period"). Product Sales, net, include Company Product Sales and Contract Manufacturing Sales.
  • Total revenues increased by $4.1 million to $11.6 million in the first quarter of 2021 versus $7.4 million in Prior Period. The increase was driven primarily by timing of orders from private label customers, wholesale restocking and fewer Canadian supply constraints that were present
  • Research and development services and other revenues will not be consistent and will vary, from period to period, depending on the required timeline of each development project and/or agreement.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: abandoned, abated, absence, acknowledgment, Albany, anniversary, API, appoint, Artesa, ATM, begun, budget, burn, Cigna, Cintex, collateral, conservation, consummation, Coupon, customarily, DDTL, deleveraging, dispensing, dispute, Distinguishing, divested, enclosed, enjoin, entry, equitization, Estonian, exploratory, face, FCL, FDIC, fill, Florida, foregoing, forma, formally, forward, FSB, function, halting, IAS, imposed, innovator, institution, insufficient, interchangeable, lead, led, lowest, mandatorily, MDL, Nantahala, National, NDA, Noteholder, onsite, pari, passu, pharmacist, physician, pro, proceeded, prorated, protocol, reached, recalled, recapitalization, recipient, refinance, remanded, requisite, rescinded, restocking, resume, retention, Riley, satisfaction, SBA, SCL, Silverback, Society, standstill, sterile, Submission, substituted, suspend, trust, undertook, version, vote, voting, Walgreen, WBAD, Wednesday, Wilmington, workplace, workspace
Removed: alternate, Amerisource, answered, anticipated, appeal, began, Bergen, bioequivalent, Boot, ceasing, challenging, chose, commencing, comparing, comparison, complex, concentrate, continuity, counter, counterclaimed, deadline, declared, declining, demanded, dermatologist, disclosed, disease, disrupt, disruption, downturn, Econdisc, economy, eliminating, ensuring, erosion, exceeding, execute, extraordinary, extremely, Fundamental, gave, guarantee, high, initiative, instability, Leadership, light, local, lost, lowering, manage, matured, NaN, Organization, pace, partial, patient, permanently, pertaining, political, positioning, presence, prevent, priority, proliferate, prolonged, protect, reconsider, redeemed, requested, SA, safety, sought, specialty, stable, stay, strain, stringent, suggested, targeted, Team, temporary, TICO, TTM, typical, Valdepharm, waiver, wave, weak, World